Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study

Purpose To investigate the impact of delayed adjuvant imatinib on GIST patients with high risk of recurrence. Method Adult GIST patients were retrospectively collected from our hospital between 2011 and 2018, and patients having high risk of recurrence were included for subsequent analyses. The prim...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology Vol. 148; no. 6; pp. 1493 - 1500
Main Authors: Qianyi, Wan, Mei, Xu, Rui, Zhao, Yong, Wang, Yutao, Wu, Xiaoding, Shen, Xiaoting, Wu
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2022
Springer Nature B.V
Subjects:
Adjuvants, Immunologic - therapeutic use
Adult
Antineoplastic Agents - therapeutic use
Cancer
Cancer Research
Chemotherapy, Adjuvant
Cohort analysis
Gastrointestinal cancer
Gastrointestinal Stromal Tumors - drug therapy
Gastrointestinal Stromal Tumors - pathology
Gastrointestinal Stromal Tumors - surgery
Hematology
Humans
Imatinib
Imatinib Mesylate - therapeutic use
Inhibitor drugs
Internal Medicine
Medical research
Medicine
Medicine & Public Health
Metastasis
Mutation
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Oncology
Original Article – Clinical Oncology
Original – Clinical Oncology
Patients
Retrospective Studies
Surgery
Survival
Targeted cancer therapy
Tumors
Imatinib
Recurrence-free survival
Gastrointestinal stromal tumor
ISSN:0171-5216, 1432-1335, 1432-1335
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To investigate the impact of delayed adjuvant imatinib on GIST patients with high risk of recurrence. Method Adult GIST patients were retrospectively collected from our hospital between 2011 and 2018, and patients having high risk of recurrence were included for subsequent analyses. The primary endpoint was recurrence-free survival (RFS). Results According to the interval between the radical surgery and the beginning of adjuvant imatinib, 222 patients were divided into three groups: group A (≤ 2 months, n  = 41), group B (2–≤ 4 months, n  = 113), and group C (4–≤ 6 months, n  = 68). Univariate, multivariate, and survival analyses all showed that patients in group A had significantly more favorable RFS than those in group C but not group B, and patients taking adjuvant imatinib for over 12 months were also associated with longer RFS comparing to adjuvant imatinib of ≤ 12 months. When stratified by the duration of adjuvant imatinib, no significant differences were found in RFS among groups A, B, and C for adjuvant imatinib of ≤ 12 months. While for adjuvant imatinib of over 12 months, both groups A and B had significantly more favorable RFS than group C, and no significant difference in RFS was found between group A and B. Conclusion Delayed postoperative adjuvant imatinib for over 4 months in patients with high risk of recurrence of GIST may lead to worse RFS, and longer treatment with shorter delay has best results.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0171-5216
1432-1335
1432-1335
DOI:10.1007/s00432-021-03749-6